Pharmaceutical company Mallinckrodt plc (MNK) Tuesday reported third-quarter results that topped analysts’ estimates, sending its shares up 10% during pre-market hours.
Earnings rose to $113.8 million, or $1.34 per share, from $63.7 million, or $0.66 per share in the year-over period. On an adjusted basis, earnings stood at $2.10 per share, higher than $1.80 per share expected by analysts.
Net sales rose 6.6% to $640 million versus the Street estimate of $633.43.
“Mallinckrodt performed well in the third quarter driven by strong customer demand for our hospital products and effective expense management. This tight expense control also helped us support increased R&D investments in our innovative pipeline,” CEO Mark Trudeau said.
SG&A expenses were $164.0 million or 25.6% of net sales, as compared to $186.3 million, or 31% a year ago.
Buoyed by the strong third quarter performance, the UK-based firm raised its adjusted diluted EPS guidance for fiscal 2018 to $7.00 to $7.20.
During Q3, Mallinckrodt also reduced total debt by $170.6 million and ended the quarter with net debt below $6.0 billion.
Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.
Most Popular
Should investors worry about Micron’s (MU) weak Q4 results and guidance?
The semiconductor industry is a rapidly growing business segment that currently thrives on the digital transformation wave. The demand for memory chips and other semiconductor products increased over the years,
What has Bed Bath & Beyond (BBBY) outlined for this fiscal year?
Shares of Bed Bath & Beyond (NASDAQ: BBBY) were up on Friday, a day after the company delivered disappointing results for the second quarter of 2022. The company reported a
NKE Earnings: Highlights of Nike’s Q1 2023 results
Nike, Inc. (NYSE: NKE) has reported a decrease in net profit for the first quarter of 2023, despite a modest increase in revenues. The company's stock suffered a big loss
